@JessieChimni @aedwards02 this is not allogeneic as u are imagining it. pts had undergone allo stem cell transplant previously & CAR T were donor derived from haplo or matched donors. they would not be rejected as the transplanted immune system wouldn't view as foreign. this is not relevant to SANA etc

@aedwards02 @JessieChimni this is not allogeneic as u are imagining it. pts had undergone allo stem cell transplant previously & CAR T were donor derived from haplo or matched donors. they would not be rejected as the transplanted immune system wouldn't view as foreign. this is not relevant to SANA etc

@allisonoconn @DanaFarber congratulations!!!

@mesandhya1 Congrats Sandhya! So happy to have you working with us now!

@CoffeltLab @RobWiesheu @sarah_cedwards He can fly with the bench still attached!

im not sure the Lyell binder is the same as used in the Hutch trials - are you sure? But the Hutch also had a solid tumor trial (NCT02706392). they publicly presented that there was some high grade lung tox seen so possible same tox (if i remember correctly, they attributed to CRS FWIW). nevertheless, i agree, this is circumstantial. but it almost always is in clinical medicine.

if there's no anti-tumor activity, the cells (for whatever reason) are likely not active drug. the drug that goes into each individual is not the same. some pts get CD19 CAR, cells dont expand, and pt doesnt develop b cell aplasia. that doesnt mean B cells arent targeted by active CAR T cells. also maybe there are differences in ROR1 expression level between pts (on normal tissue and or/on tumor) that alter expansion/activation kinetics. many many factors.

it's possible that on-target, off tumor tox only occurs after T cell expansion driven by cells responding to tumor, and may not occur if T cells dont activate, expand etc. its an unknown. nothing in clinical medicine is simple. but IMO ROR1 expression in lung makes it unlikely that a supercharged CAR T cells will be able to thread a therapeutic window here (similar to MSLN experience)

@aedwards02 @Satpathology the on-target, off tumor lung tox is well described in preclinical models (. Oncternal also prob has pneumonitis w/ROR1-CAR (called pneumonia in their press release FWIW) and previous ROR1 academic trials had g4/g5 lung events. if it looks like a duck...

@pengwu321 @DevBioStanford @StanfordPeds @TriIMDPhD @CincyChildrens @ChildrensCBDI Amazing news - congrats Peng!

Not sure this adds any evidence for IL2 as there were no responses: "No patient exhibited an objective clinical response to treatment." So not sure how can say the IL2 was necessary in the absence of real responses. Granted, "five patients, including two patients receiving low-dose IL-2 and three patients receiving high-dose IL-2, demonstrated marked reduction at individual tumor sites" but these weren't responses AND it was seen equally in low dose IL2 to high dose IL2. I always assumed IL2 is needed but can't find any clinical info saying that...

@DrBetofMDPhD @StanfordCancer @OncoAlert can you post/send the paper? i couldnt find anything when i tried to dig

@DrBetofMDPhD @StanfordCancer @OncoAlert Very cool to see this technology now utilized in patients - hoping to see more remote control enhancements in cell therapies! @DrBetofMDPhD - is there clinical data showing IL-2 is necessary for TIL success in trials? i couldn't find a trial...

@Satpathology congrats Ansu, Kevin, @CartographyBio & @GileadSciences - looking forward to watching your science develop into drugs!

Recruitment! We are looking for a candidate for the lab (postdoc or scientist) with experience in yeast and/or phage display to work on some cool bioengineering projects for immunotherapy development! Please reach out if interested! Science friends, please retweet!

@MMaversMDPhD @EvanWeberPhD My lab demo’d 3-4 different machines, loved the EVE-HT from Nanotek - think it was the cheapest too potentially. They liked their single slide counter as well and bought two of those - they were less than half the $ of our nexelcom

@drug_smolecules @augcccaaauag @BertrandBio @MSubklewe @bradloncar @ByMadeleineA @JacobPlieth @Prof_Oak_ 19 comes up earlier. thats why it works well for pre-B ALL (and pro-B)

@btsxbiotech @MSubklewe @bradloncar @ByMadeleineA @JacobPlieth @Prof_Oak_ @BertrandBio Need to wait to see clinical results - who knows! Hopefully they all work well so there are many options for patients in need!

@drug_smolecules @BertrandBio @MSubklewe @bradloncar @ByMadeleineA @JacobPlieth @Prof_Oak_ The clinical results are the only thing that matters. Biology is complicated - in any case, hopefully we will find out as these agents get into trials.